Compare · DXCM vs PETV
DXCM vs PETV
Side-by-side comparison of DexCom Inc. (DXCM) and PetVivo Holdings Inc. (PETV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and PETV operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $33.10B, about 2670.9x PETV ($12.4M).
- Both names hit the wire about 6 times in the past 4 weeks.
- DXCM has more recent analyst coverage (25 ratings vs 1 for PETV).
- Company
- DexCom Inc.
- PetVivo Holdings Inc.
- Price
- -
- -
- Market cap
- $33.10B
- $12.4M
- 1M return
- -2.13%
- -
- 1Y return
- +29.24%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- News (4w)
- 6
- 6
- Recent ratings
- 25
- 1
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
PetVivo Holdings Inc.
PetVivo Holdings, Inc., a veterinary biotech and biomedical device company, engages in the licensing and commercializing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Kush, a veterinarian-administered joint injection for the treatment of osteoarthritis and lameness in dogs and horses. The company's pipeline products include 17 therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. is headquartered in Minneapolis, Minnesota.
Latest DXCM
- Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin
- Barclays initiated coverage on Dexcom with a new price target
- Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time
- Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading
- EVP Chief People & Culture Off Stern Sadie sold $220,975 worth of shares (2,565 units at $86.15) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 123,478 units (SEC Form 4)
- Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care
- EVP Chief Legal Compliance Off Brown Michael Jon sold $142,868 worth of shares (1,700 units at $84.04) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 99,885 units (SEC Form 4)
- Director Augustinos Nicholas sold $679,769 worth of shares (8,089 units at $84.04) as part of a pre-agreed trading plan (SEC Form 4)
- DexCom Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Dexcom Promotes Jereme Sylvain to Chief Operating Officer
Latest PETV
- PETVIVO ANNOUNCES RELEASE OF TWO REASEARCH ABSTRACTS AND UPCOMING CONFERENCE PRESENTATIONS ON OSTEOARTHRITIS IN RHESUS MACAQUES
- PetVivo Holdings Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- PetVivo Holdings Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Michael Handley Joins PetVivo Holdings, Inc. Board of Directors
- Jaime Pickett Joins PetVivo Holdings, Inc. Board of Directors
- Director Rudelius Robert James was granted 3,497 shares, increasing direct ownership by 0.87% to 406,889 units (SEC Form 4)
- PETVIVO ANIMAL HEALTH, INC. RELEASES CONFERENCE AND EXHIBIT SCHEDULE FOR 2026-2027
- Large owner A.L. Sarroff Fund, Llc bought $40,022 worth of shares (58,602 units at $0.68) (SEC Form 4)
- Amendment: Chief Financial Officer Lowenthal Garry N was granted 31,250 shares (SEC Form 4)
- Amendment: Chief Executive Officer Lai John was granted 31,250 shares, increasing direct ownership by 1% to 2,413,163 units (SEC Form 4)